510(k) Summary of Safety and Effectiveness

Device Name

Model 342GE High Resolution Brain Coil

Applicability

Compatible with GE Signa 1.5T MR systems

operating at 4.X - LX software levels and the NV/i

system

Reason for 510(k)

New device

Classification Name

Magnetic Resonance Diagnostic Device

Device Classification Panel

Radiology

Device Classification Number

892.1000

Product Code

90LNH

Common Name

Magnetic Resonance Imaging Coil

Proprietary Name

Model 342GE High Resolution Brain Coil

Establishment Registration Number

2183683

Address of MFG Facility 10437 Innovation Drive Milwaukee, WI 53226 IGC-Medical Advances Inc.

Point of Contact

Michael Leigh

Manager, Regulatory Affairs and Quality Assurance

(414) 258-3808 Ext. 206

Classification

Class II

Intended Uses

Diagnostic Uses

High resolution imaging of the brain utilizing

standard pulse sequences, perfusion weighted imaging, diffusion weighted imaging, functional

MRI, and intracranial MR angiography.

Anatomic Regions

Soft tissue and vascular structures of the brain from

the brain apex through the pons.

Standards

Performance Standards

None Established under Section 514

Voluntary Safety Standards

UL 2601-1 Medical Electrical Equipment, Part I: General Requirements for Safety

UL 94 Tests for Flammability of Plastic Materials

IEC 601-1 General Safety Requirements for Medical Electrical Equipment

Overview

The Radiology Devices Panel considered potential concerns regarding the safe and effective operation of Magnetic Resonance Diagnostic Devices when they recommended reclassification to Class II on July 27, 1987. After reclassification, the FDA's Center for Devices and Radiological Health (CDRH) released a draft guidance document for the content and review of Magnetic Resonance Diagnostic Device premarket notification submissions that offered clarification of these concerns. Due to considerable technological advances in MRDDs, CDRH issued an updated guidance document on November 14, 1998. The following is a summary of the information contained within this premarket notification that addresses these concerns:

The GE Signa 1.5T MRI system operated with the Medical Advances High Resolution Brain Coil is substantially equivalent to the same system operated with the legally marketed predicate device listed in section 4.0, within the Class II definition of Magnetic Resonance Diagnostic Device with respect to the safety parameter action levels:

Safety Parameters

Maximum Static Magnetic Field: No change

Rate of Magnetic Field Strength Change: No change

RF Power Deposition: No change

Acoustic Noise Levels: No change

Imaging Performance Parameters

Specification Volume: No change

Signal-to-Noise Ratio: No change

Image Uniformity: No change

Geometric Distortion: No change

Slice Thickness and Gap:

No change

High Contrast Spatial Resolution:

No change

General Safety and Effectiveness Concerns

The device contains instructions for use. It includes indications for use, precautions, cautions, contraindications, warnings and quality assurance testing. This information assures safe and effective use of the device.

Substantial Equivalence Summary

The GE Signa 1.5T MRI system operated with the Medical Advances High Resolution Brain Coil addressed in this PMN, has the same intended use and technological characteristics as the same system operated with the identified legally marketed predicate device. The use of this coil does not affect the GE Signa 1.5T system safety parameter specifications.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

DEC 2.2 2000

Michael J. Leigh Manager, Regulatory Affairs and Quality Assurance IGC-Medical Advances Inc. 10437 Innovation Drive Milwaukee, WI 53226 Re: K003685

Model 342GE-64: High Resolution

Brain Coil

Dated: November 27, 2000 Received: November 30, 2000

Regulatory class: II

21 CFR 892.1000/Procode: 90 MOS

Dear Mr. Leigh:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours.

Daniel G. Schultz, M.D.

Captain, USPHS

Acting Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

| | | | Pag | e <u>1</u> of <u>1</u> |
|--|---|--------------------------------------|--------------------------------------|---|
| | | | | |
| 510(k) Number (if know | wn): | | | |
| Device Name: | Model 342GE Hi | gh Resolution | Brain Coil | - |
| Indications for Use: | | | | |
| High-resolution imagir MRI, and intracranial I | ng, perfusion weighte MR angiography of th | d imaging, diff ne soft tissue ar | fusion weighted and vascular stru | l imaging, functional actures of the brain. |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | · | |
| | | | | |
| | | | | |
| | | | | |
| (PLEASE DO NOT WE | RITE BELOW THIS L | INE-CONTINU | JE ON ANOTH | ER PAGE IF NEEDEI |
| Cor | ncurrence of CDRH, | Office of Device | e Evaluation (C | |
| 33, | | | · | |
| | | | | |
| | | | | |
| | | | | • . |
| | | | | |
| (| | | | |
| Prescription Use (Per 21 CFR 801.109) | | OR | Over-The | e-Counter Use |
| (1 61 21 01 11 001. 103) | (da s | 11 Kham | ((| Optional Format 1-2-9 |
| | Division | Sign-Off) | PART | |
| | Division | of Reproductive, 2 | | |
| | and Radio 510(k) N | | 3685 | - |
| | 210(v) 11 | | | |